Mallinckrodt, the distributor of Acthar, provides comprehensive support for you and your patients. This includes access and reimbursement assistance, as well as patient injection training. Support specialists from the Acthar Support & Access Program (A.S.A.P.) coordinate all of these services to ensure efficient, seamless access to Acthar.
When you prescribe Acthar for a patient, A.S.A.P. jumps into action. It’s important for your office staff to respond to A.S.A.P. requests quickly throughout the process.
If you have any questions about A.S.A.P., please call 1-888-435-2284, Monday through Friday, between 8 AM and 8 PM ET.
As one aspect of the support process, A.S.A.P. identifies patients who may be eligible to receive Acthar at a $0 co-pay. These patients are US permanent residents who are (or have a legal representative who is) at least 18 years old, have been prescribed Acthar for an approved indication, and are commercially or privately insured. The $0 co-pay program is not available to patients insured by a federal or state healthcare plan or where prohibited by law. (A.S.A.P. will discuss other options for financial assistance with patients who are not eligible for this program.)
Eligible patients receive:
Terms and conditions apply:
H.P. Acthar® Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.
Warning and Precautions
Please see full Prescribing Information for additional Important Safety Information.